Lanreotide

see Lanreotide for Acromegaly

Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and marketed under the trade name Somatuline. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for sale in the United States by the Food and Drug Administration (FDA) on August 30, 2007.

Zhang et al., described a patient with a vasopressin-secreting atypical neurocytoma of the sellar and cavernous sinus region. Following subtotal resection via endoscopic transsphenoidal surgery, the residual tumor showed increased FDG uptake and high somatostatin receptor expression on a 68Ga-DOTA-TATE PET/CT scan. Somatostatin receptor ligand (SRL) therapy with lanreotide (120 mg Q28d) was initiated, and 4 years later the residual tumor remains stable with decreased FDG tumor uptake. Immunocytochemical somatostatin receptor 2 (SSTR2) and SSTR5 expression was further confirmed in > 80% in a series of neurocytoma tissues.

They described the first use of SRL therapy in atypical NC and the results support consideration of adjuvant SRL therapy in NC refractory to surgical removal. The findings further raise the possibility of SSTR-directed peptide receptor radionuclide therapy (PRRT) as NC therapy ¹⁾.

The current long-acting somatostatin analogs SAs, lanreotide and octreotide, show equivalence in their control of symptoms and no significant difference in their ability to normalize serum growth hormone GH and insulin like growth factor IGF-1 ²⁾.

Although a number of studies concerning presurgical treatment with lanreotide or octreotide exist, there are few prospective large-scale randomized trials comparing the effects of lanreotide and octreotide, and thus no definite conclusion has yet been achieved.

Lanreotide ATG and octreotide LAR may therefore have similar effects in clinic according to the current data ³⁾.